Bibliographic Details
| Title: |
Transcatheter arterial and venous embolisation with α-hexyl cyanoacrylate MagicGlue®: short-term safety and efficacy outcomes |
| Authors: |
Hamza Sawalha, Olivier Chevallier, Mohamed Fouad, Taninokuchi Tomassini Makoto, Comby Pierre-Olivier, Ludwig Serge Aho-Glele, Romaric Loffroy |
| Source: |
CVIR Endovascular, Vol 8, Iss 1, Pp 1-10 (2025) |
| Publisher Information: |
SpringerOpen, 2025. |
| Publication Year: |
2025 |
| Collection: |
LCC:Diseases of the circulatory (Cardiovascular) system |
| Subject Terms: |
Embolisation, Artery, Vein, Cyanoacrylate, Outcomes, Diseases of the circulatory (Cardiovascular) system, RC666-701 |
| More Details: |
Abstract Purpose Our purpose was to assess the feasibility and the short-term safety and efficacy outcomes of a wide range of transcatheter arterial and venous embolisation procedures done using α-hexyl-cyanoacrylate (AHCA)-MagicGlue® in patients with bleeding and non-bleeding disorders. Methods This single-centre retrospective study included consecutive patients who underwent emergent or planned AHCA-MagicGlue® transcatheter embolisation between February 2019 and September 2023. Technical success, clinical success, 30-day mortality, and complication rates were evaluated. Results We included 101 patients with a mean age of 49.9 ± 20.5 years who underwent arterial (n = 43, 42.6%) or venous (n = 58, 57.4%) embolisation for bleeding (n = 16, 15.8%) or other reasons (n = 85, 84.2%). The technical success rate was 100%. After a mean follow-up of 2.2 months, the clinical success rate was 94% in patients with bleeding and 95% in other patients; 1 patient died of multi-organ failure unrelated to the procedure. In the 22 patients with prostatic artery embolisation, statistically significant improvements were recorded at 3 months versus baseline for the International Prostate Symptoms Score (IPSS) (10.0 ± 5.8 vs. 20.8 ± 7.3, p = 0.001), IPSS quality-of-life score (2.0 ± 1.4 vs. 5.0 ± 1.0; p = 0.001), and prostate volume (67.8 ± 38.0 mL vs. 96.7 ± 47.4 mL, p = 0.001). Adverse events occurred in 11 (10.9%) patients and were major in 4 and minor in 7 patients. Conclusions MagicGlue® transcatheter arterial and venous embolisation is feasible, effective, and safe for bleeding and non-bleeding conditions across a broad range of anatomic sites. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2520-8934 |
| Relation: |
https://doaj.org/toc/2520-8934 |
| DOI: |
10.1186/s42155-025-00535-0 |
| Access URL: |
https://doaj.org/article/05694a89b82843658ef51038449a6861 |
| Accession Number: |
edsdoj.05694a89b82843658ef51038449a6861 |
| Database: |
Directory of Open Access Journals |
